New drug trial targets tough pancreatic cancer
NCT ID NCT06396091
Summary
This early-stage study is testing the safety of a new drug, zolbetuximab, when given alongside standard chemotherapy to people with advanced pancreatic cancer that has spread. The drug works by attaching to a specific protein on cancer cells to help the immune system attack the tumor. The main goal is to find a safe dose and see how well people tolerate the combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.